Understanding Bare Lymphocyte Syndrome Type I (BLS-I)

Bare Lymphocyte Syndrome Type I (BLS-I), also known as MHC Class I deficiency, is an exceptionally rare genetic condition that affects the immune system’s ability to communicate ^[1]. Under normal circumstances, most cells in your body use a “display case” called Major Histocompatibility Complex (MHC) Class I to show the immune system what is happening inside them ^[2]. In BLS-I, these display cases are missing or severely reduced, leaving the immune system partially “blind” to certain threats ^[3].

Because it is so rare, many doctors may never see a case in their entire career. This often leads to a long journey toward an accurate diagnosis.

An Exceptionally Rare Condition

BLS-I is among the rarest immune disorders in the world. As of historical literature reviews, fewer than 50 unique individuals have been documented ^[1]. This small number does not establish current prevalence, but explains why local doctors may be unfamiliar with it.

The condition is autosomal recessive, meaning a person must inherit a copy of the mutated gene from both parents to develop the syndrome ^[1]. Most cases involve mutations in genes called TAP1, TAP2, or TAPBP (tapasin), which are responsible for loading the “display cases” before they reach the cell surface ^[4][2]. A much rarer form involves the B2M gene, which helps build the structure of the display case itself ^[3].

The Long Journey to Diagnosis

The “diagnostic odyssey”—the time between the first symptoms and an accurate diagnosis—is often very long for people with BLS-I.

• Diagnostic Delays: One small historical cohort study found that the median delay in diagnosis was approximately 14 years ^[4].
• Late Diagnosis: The same cohort reported a median age of 19 years old at diagnosis, though it can be found much earlier or later ^[4].
• Misdiagnosis: Because the symptoms can look like more common autoimmune diseases, such as granulomatosis with polyangiitis, some patients are initially treated with the wrong medications ^[1][5].

A Wide Spectrum of Symptoms

One of the most challenging aspects of BLS-I is that it does not look the same in everyone. The severity varies enormously depending on the affected gene and residual immune function.

1. Asymptomatic or Mild

Surprisingly, some individuals with very low MHC Class I levels remain healthy and asymptomatic (showing no symptoms) well into their adult lives ^[6][7]. In these cases, the body’s other immune defenses (like Natural Killer cells) may compensate for the missing MHC Class I. Others may only experience mild respiratory infections that respond well to standard antibiotics ^[6].

2. Moderate to Severe Respiratory Issues

Many people with BLS-I experience recurrent sinopulmonary infections (infections of the sinuses and lungs) ^[1]. Over time, repeated infections can lead to bronchiectasis, a condition where the airways of the lungs become permanently widened and scarred ^[4]. In one small study of 11 patients, 10 had developed bronchiectasis ^[4].

3. Skin and Eye Manifestations

A frequently reported feature of BLS-I is the development of granulomatous skin lesions—deep, chronic skin ulcers that can be difficult to heal ^[1]. These often appear on the legs or the middle of the face ^[4]. Some patients also develop uveitis, which is inflammation inside the eye that can affect vision ^[4][1].

Why Is It Hard to Detect?

Standard blood tests often fail to catch BLS-I. For example, a common immune cell count called a CD8+ T-cell count may appear normal in about half of all cases ^[1].

Doctors usually confirm a diagnosis using:

• Flow Cytometry: A specialized test that estimates the relative expression of the “display cases” (HLA-ABC) on the surface of white blood cells ^[4].
• Genetic Testing: Identifying the specific mutation in the TAP1, TAP2, TAPBP, or B2M genes ^[1].

Understanding where you or your child falls on this spectrum is the first step in creating a personalized care plan with an immunology specialist.